Will AstraZeneca's SGLT2-favoring data win the class a shot at front-line diabetes use?
admin 13th June 2017 Uncategorised 0Back in March, a real-world analysis showed SGLT2 diabetes meds from AstraZeneca, Johnson & Johnson and the Eli Lilly-Boehringer team could dramatically cut heart failure hospitalizations and deaths. Now, new analyses confirm those findings—and may make a case for using the meds earlier in treatment, AZ’s execs suggest.
More: Will AstraZeneca's SGLT2-favoring data win the class a shot at front-line diabetes use?
Source: fierce